{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:51Z","timestamp":1753889991221,"version":"3.41.2"},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMIR"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Parkinsonism is a term used for the collection of clinical features that cause\nmovement disorders similar to those in Parkinson\u2019s disease. Accurate differentiation of these disorders\nis critical for the treatment and prognosis of any disease. Fluorine-18 N-(3-fluoropropyl)-2\u03b2-\ncarboxymethoxy-3\u03b2-(4-iodophenyl) nortropane (F-18 FP-CIT) has been used in the evaluation of parkinsonism\nby its uptake in the dopamine active transporter (DAT) of the striatum. Its uptake in other areas of\nthe brain, such as serotonin transporter (SERT) in the midbrain or thalamus, is also recognised.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To investigate whether midbrain SERT uptake of F-18 FP-CIT on positron emission tomography\n(PET) could be applied to the differentiation of parkinsonism in combination with striatal DAT\nuptake.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This retrospective study included clinically diagnosed three essential tremors (ET), 53 parkinsonism\npatients (21 idiopathic Parkinson\u2019s disease (IPD), 6 multiple system atrophy \u2013 cerebellar\ntype (MSA-C), 7 multiple system atrophy - parkinsonian type (MSA-P), 8 vascular parkinsonism (VP),\nand 11 drug-induced parkinsonism (DIP)), and 16 healthy controls. The patient group consisted of 29\nmen and 27 women (age mean \u00b1 SD years, 69.9 \u00b1 8.5 and 69.2 \u00b1 8.9, respectively), and the healthy\ncontrols consisted of 8 men and 8 women (age mean \u00b1 SD years, 64.5 \u00b1 8.2 and 64.3 \u00b1 7.6, respectively).\nMean standardized uptake values (SUVs) and activity volumes were measured from the visualized\nFP-CIT uptake of the midbrain (substantia nigra and dorsal raphe nucleus) as well as the striatum (caudate\nnucleus and putamen). The mean SUVs of the occipital region were measured as the background\nactivity. The semiquantitative binding ratio (BR) was calculated using the following formula: BR =\n(SUVmean of the region of interest \u2212 SUVmean of background)\/SUVmean of the background. SUV,\nvolume, and BR in each type of parkinsonism were compared with those in healthy controls using both\nnonparametric and parametric methods. The correlation between the visual score of the qualitative\nanalysis and the BR was examined.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Except for the dorsal raphe nucleus in VP, the midbrain BRs in all parkinsonism showed a\nstatistically significant decrease compared to those in healthy controls. Both midbrain and striatal BRs\nwere significantly decreased only in patients with IPD or MSA-P; a greater decrease of substantia nigra\nBR was identified in MSA-P than in IPD (p &lt; 0.05). The striatal BRs in MSA-C, VP, and DIP showed\nno significant difference from those in healthy controls. Finally, four patterns of uptake were identified:\n1) decreased striatal and midbrain uptake for IPD and MSA-P, 2) normal striatal uptake and decreased\nmidbrain uptake (both substantia nigra and dorsal raphe nucleus) for MSA-C and DIP, 3) normal\nstriatal uptake and decreased substantia nigra uptake (without decreased dorsal raphe nucleus uptake)\nfor VP, and 4) normal striatal and midbrain uptake for ET.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The possible differential diagnoses were split into two groups when only striatal uptake was considered but they were divided into four groups after adding midbrain uptake. Although additional midbrain F-18 FP-CIT uptake still could not make a definitive diagnosis, it could provide another piece of information and specific diagnostic guidelines for the differentiation of parkinsonism.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573405619666230124142725","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T15:14:31Z","timestamp":1675437271000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation\nof Essential Tremor and Parkinsonism"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-1906","authenticated-orcid":true,"given":"Kyung-Hoon","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Gachon University College of Medicine, Gil Medical Center, Incheon 21565, South\nKorea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-2903","authenticated-orcid":true,"given":"Haejun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gachon University College of Medicine, Gil Medical Center, Incheon 21565, South\nKorea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-1338","authenticated-orcid":true,"given":"Young Hee","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gachon University College of Medicine, Gil Medical Center, Incheon 21565, South\nKorea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"Bloem B.R.","year":"2021","unstructured":"Bloem B.R.; Okun M.S.; Klein C.; Parkinson\u2019s disease. Lancet 2021,397(10291),2284-2303","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"Armstrong M.J.","year":"2020","unstructured":"Armstrong M.J.; Okun M.S.; Diagnosis and treatment of Parkinson disease. JAMA 2020,323(6),548-560","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Parkinson disease. Nat Rev Dis Primers 2017,3(1),17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14737175.2019.1569515","volume":"19","author":"Margolesky J.","year":"2019","unstructured":"Margolesky J.; Approaching drug-induced parkinsonism from a neurohospitalist perspective. Expert Rev Neurother 2019,19(2),93-95","journal-title":"Expert Rev Neurother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","volume":"7","author":"Ward K.M.","year":"2018","unstructured":"Ward K.M.; Citrome L.; Antipsychotic-related movement disorders: Drug-Induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther 2018,7(2),233-248","journal-title":"Neurol Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","volume":"20","author":"Brigo F.","year":"2014","unstructured":"Brigo F.; Erro R.; Marangi A.; Bhatia K.; Tinazzi M.; Differentiating drug-induced parkinsonism from parkinson\u2019s disease: An update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014,20(8),808-814","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/aian.AIAN_194_18","volume":"22","author":"Dhananjalee Alahakoon A.M.B.","year":"2019","unstructured":"Dhananjalee Alahakoon A.M.B.; Udagedara T.B.; Goonaratna I.; Vascular parkinsonism: A review on management updates. Ann Indian Acad Neurol 2019,22(1),17-20","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11910-019-1019-7","volume":"19","author":"Ma K.K.Y.","year":"2019","unstructured":"Ma K.K.Y.; Lin S.; Mok V.C.T.; Neuroimaging in vascular parkinsonism. Curr Neurol Neurosci Rep 2019,19(12),102","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/642764","volume":"2015","author":"Solla P.","year":"2015","unstructured":"Solla P.; Cannas A.; Arca R.; Fonti D.; Orofino G.; Marrosu F.; Focal 123 I-FP-CIT SPECT abnormality in midbrain vascular parkinsonism. Case Rep Neurol Med 2015,2015,1-3","journal-title":"Case Rep Neurol Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"Jankovic J.","year":"2020","unstructured":"Jankovic J.; Tan E.K.; Parkinson\u2019s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020,91(8),795-808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"Connolly B.S.","year":"2014","unstructured":"Connolly B.S.; Lang A.E.; Pharmacological treatment of parkinson disease: A review. JAMA 2014,311(16),1670-1683","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-004-1733-4","volume":"32","author":"Stoffers D.","year":"2005","unstructured":"Stoffers D.; Booij J.; Bosscher L.; Winogrodzka A.; Wolters E.C.; Berendse H.W.; Early-stage [123I]\u03b2-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of parkinson\u2019s disease. Eur J Nucl Med Mol Imaging 2005,32(6),689-695","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-2007-971174","volume":"27","author":"Tuite P.","year":"2007","unstructured":"Tuite P.; Krawczewski K.; Parkinsonism: A review-of-systems approach to diagnosis. Semin Neurol 2007,27(2),113-122","journal-title":"Semin Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","volume":"5","author":"Tolosa E.","year":"2006","unstructured":"Tolosa E.; Wenning G.; Poewe W.; The diagnosis of parkinson\u2019s disease. Lancet Neurol 2006,5(1),75-86","journal-title":"Lancet Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/jnnp.69.5.590","volume":"69","author":"Clarke C.E.","year":"2000","unstructured":"Clarke C.E.; Davies P.; Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2000,69(5),590-594","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/jcbfm.1994.131","volume":"14","author":"Laruelle M.","year":"1994","unstructured":"Laruelle M.; Wallace E.; Seibyl J.P.; Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994,14(6),982-994","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/jm00114a027","volume":"34","author":"Neumeyer J.L.","year":"1991","unstructured":"Neumeyer J.L.; Wang S.Y.; Milius R.A.; [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: High-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991,34(10),3144-3146","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00259-014-2785-8","volume":"41","author":"Koch W.","year":"2014","unstructured":"Koch W.; Unterrainer M.; Xiong G.; Extrastriatal binding of [(1)(2)(3)I]FP-CIT in the thalamus and pons: Gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging 2014,41(10),1938-1946","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2191-219X-3-34","volume":"3","author":"Borgers A.J.","year":"2013","unstructured":"Borgers A.J.; Alkemade A.; Van de Giessen E.M.; Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus. EJNMMI Res 2013,3(1),34","journal-title":"EJNMMI Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/mds.23179","volume":"25","author":"Roselli F.","year":"2010","unstructured":"Roselli F.; Pisciotta N.M.; Pennelli M.; Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study. Mov Disord 2010,25(12),1853-1859","journal-title":"Mov Disord"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cpet.2009.05.006","volume":"4","author":"Stehouwer J.S.","year":"2009","unstructured":"Stehouwer J.S.; Goodman M.M.; Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: Dopamine, serotonin, and norepinephrine. PET Clin 2009,4(1),101-128","journal-title":"PET Clin"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/jcbfm.2014.82","volume":"34","author":"Gryglewski G.","year":"2014","unstructured":"Gryglewski G.; Lanzenberger R.; Kranz G.S.; Cumming P.; Meta-analysis of molecular imaging of serotonin transporters in major depression. J Cereb Blood Flow Metab 2014,34(7),1096-1103","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.nucmedbio.2008.02.008","volume":"35","author":"Ettlinger D.E.","year":"2008","unstructured":"Ettlinger D.E.; H\u00e4usler D.; Wadsak W.; Metabolism and autoradiographic evaluation of [18F]FE@CIT: A Comparison with [123I]\u03b2-CIT and [123I]FP-CIT. Nucl Med Biol 2008,35(4),475-479","journal-title":"Nucl Med Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.116.182139","volume":"58","author":"Joling M.","year":"2017","unstructured":"Joling M.; Vriend C.; van den Heuvel O.A.; Analysis of extrastriatal 123I-FP-CIT binding contributes to the differential diagnosis of parkinsonian diseases. J Nucl Med 2017,58(7),1117-1123","journal-title":"J Nucl Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2967\/jnumed.111.102277","volume":"53","author":"Koopman K.E.","year":"2012","unstructured":"Koopman K.E.; la Fleur S.E.; Fliers E.; Serlie M.J.; Booij J.; Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med 2012,53(7),1087-1090","journal-title":"J Nucl Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","volume":"51","author":"Ziebell M.","year":"2010","unstructured":"Ziebell M.; Holm-Hansen S.; Thomsen G.; Serotonin transporters in dopamine transporter imaging: A head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med 2010,51(12),1885-1891","journal-title":"J Nucl Med"},{"key":"ref=27","first-page":"359","volume":"48","author":"Booij J.","year":"2007","unstructured":"Booij J.; de Jong J.; de Bruin K.; Knol R.; de Win M.M.; van Eck-Smit B.L.; Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007,48(3),359-366","journal-title":"J Nucl Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"14992","DOI":"10.1038\/s41598-021-94040-8","volume":"11","author":"Oh M.","year":"2021","unstructured":"Oh M.; Lee N.; Kim C.; Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of parkinsonism. Sci Rep 2021,11(1),14992","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12883-020-01777-2","volume":"20","author":"Nicastro N.","year":"2020","unstructured":"Nicastro N.; Garibotto V.; Burkhard P.R.; Extrastriatal 123I-FP-CIT SPECT impairment in parkinson\u2019s disease \u2013 the PPMI cohort. BMC Neurol 2020,20(1),192","journal-title":"BMC Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3233\/JPD-202214","volume":"10","author":"Frings L.","year":"2020","unstructured":"Frings L.; Henninger F.; Treppner M.; [123I]FP-CIT SPECT in clinically uncertain parkinsonism predicts survival: A data-driven analysis. J Parkinsons Dis 2020,10(4),1457-1465","journal-title":"J Parkinsons Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00415-011-6076-z","volume":"258","author":"Sixel-D\u00f6ring F.","year":"2011","unstructured":"Sixel-D\u00f6ring F.; Liepe K.; Mollenhauer B.; Trautmann E.; Trenkwalder C.; The role of 123I-FP-CIT-SPECT in the differential diagnosis of parkinson and tremor syndromes: A critical assessment of 125 cases. J Neurol 2011,258(12),2147-2154","journal-title":"J Neurol"},{"key":"ref=32","first-page":"1879","volume":"39","author":"Booij J.","year":"1998","unstructured":"Booij J.; Habraken J.B.; Bergmans P.; Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with parkinson\u2019s disease. J Nucl Med 1998,39(11),1879-1884","journal-title":"J Nucl Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/jnnp-2021-327376","volume":"93","author":"Lawton M.","year":"2022","unstructured":"Lawton M.; Tan M.M.X.; Ben-Shlomo Y.; Genetics of validated parkinson\u2019s disease subtypes in the oxford discovery and tracking parkinson\u2019s cohorts. J Neurol Neurosurg Psychiatry 2022,93(9),952-959","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1111\/ene.15509","volume":"29","author":"Chen Y.P.","year":"2022","unstructured":"Chen Y.P.; Yu S.H.; Zhang G.H.; The mutation spectrum of Parkinson\u2010disease \u2010related genes in early\u2010onset parkinson\u2019s disease in ethnic Chinese. Eur J Neurol 2022,29(11),3218-3228","journal-title":"Eur J Neurol"},{"key":"ref=35","first-page":"83","volume":"30","author":"Chu Y.T.","year":"2021","unstructured":"Chu Y.T.; Tai C.H.; Lin C.H.; Wu R.M.; Updates on the genetics of parkinson\u2019s disease: Clinical implications and future treatment. Acta Neurol Taiwan 2021,30(3),83-93","journal-title":"Acta Neurol Taiwan"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/mds.28534","volume":"36","author":"Liu H.","year":"2021","unstructured":"Liu H.; Koros C.; Stroh\u00e4ker T.; A novel snca a30g mutation causes familial parkinson\u02bcs disease. Mov Disord 2021,36(7),1624-1633","journal-title":"Mov Disord"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40291-016-0216-1","volume":"20","author":"Gorostidi A.","year":"2016","unstructured":"Gorostidi A.; Mart\u00ed-Mass\u00f3 J.F.; Bergareche A.; Rodr\u00edguez-Oroz M.C.; L\u00f3pez de Munain A.; Ruiz-Mart\u00ednez J.; Genetic mutation analysis of parkinson\u2019s disease patients using multigene next-generation sequencing panels. Mol Diagn Ther 2016,20(5),481-491","journal-title":"Mol Diagn Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ajmg.b.32452","volume":"171","author":"Mata I.F.","year":"2016","unstructured":"Mata I.F.; Davis M.Y.; Lopez A.N.; The discovery of LRRK2 p.R1441S, a novel mutation for parkinson\u2019s disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet 2016,171(7),925-930","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10072-014-1945-8","volume":"36","author":"Shin H.W.","year":"2015","unstructured":"Shin H.W.; Kim J.S.; Oh M.; Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurol Sci 2015,36(2),269-274","journal-title":"Neurol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/ene.12444","volume":"21","author":"Brigo F.","year":"2014","unstructured":"Brigo F.; Matinella A.; Erro R.; Tinazzi M.; [(1)(2)(3)I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between parkin son\u2019s disease and vascular or drug-induced parkinsonisms: A meta-analysis. Eur J Neurol 2014,21(11),1369-e1390","journal-title":"Eur J Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nrl.2012.05.005","volume":"28","author":"Olivares Romero J.","year":"2013","unstructured":"Olivares Romero J.; Arjona Padillo A.; Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study. Neurologia 2013,28(5),276-282","journal-title":"Neurologia"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/RLU.0b013e3182291a7b","volume":"36","author":"Cuberas-Borr\u00f3s G.","year":"2011","unstructured":"Cuberas-Borr\u00f3s G.; Lorenzo-Bosquet C.; Aguad\u00e9-Bruix S.; Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clin Nucl Med 2011,36(11),991-996","journal-title":"Clin Nucl Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00259-009-1289-4","volume":"37","author":"Diaz-Corrales F.J.","year":"2010","unstructured":"Diaz-Corrales F.J.; Sanz-Viedma S.; Garcia-Solis D.; Escobar-Delgado T.; Mir P.; Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and parkinson\u2019s disease. Eur J Nucl Med Mol Imaging 2010,37(3),556-564","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00702-018-1863-7","volume":"125","author":"Hellwig S.","year":"2018","unstructured":"Hellwig S.; Frings L.; Masuch A.; Antidepressant treatment effects on dopamine transporter availability in patients with major depression: A prospective 123I-FP-CIT SPECT imaging genetic study. J Neural Transm (Vienna) 2018,125(6),995-1005","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13139-014-0286-0","volume":"48","author":"Seo M.","year":"2014","unstructured":"Seo M.; Oh M.; Cho M.; Chung S.J.; Lee C.S.; Kim J.S.; The effect of SSRIs on the binding of 18F-FP-CIT in parkinson patients: A retrospective case control study. Nucl Med Mol Imaging 2014,48(4),287-294","journal-title":"Nucl Med Mol Imaging"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.npp.1300036","volume":"28","author":"Kugaya A.","year":"2003","unstructured":"Kugaya A.; Seneca N.M.; Snyder P.J.; Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003,28(2),413-420","journal-title":"Neuropsychopharmacology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0924-977X(98)00013-3","volume":"9","author":"Tauscher J.","year":"1999","unstructured":"Tauscher J.; Pirker W.; de Zwaan M.; Susanne Asenbaum; Br\u00fccke T; Kasper S.; in vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 1999,9(1-2),177-179","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-0038-1623903","volume":"42","author":"Br\u00fccke T.","year":"2003","unstructured":"Br\u00fccke T.; Odin P.; Brooks D.J.; [123I]\u03b2-CIT SPECT imaging of dopamine and serotonin transporters in parkinson\u2019s disease and multiple system atrophy. Nucl Med (Stuttg) 2003,42(1),31-38","journal-title":"Nucl Med (Stuttg)"},{"key":"ref=49","first-page":"36","volume":"41","author":"Pirker W.","year":"2000","unstructured":"Pirker W.; Asenbaum S.; Hauk M.; Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000,41(1),36-44","journal-title":"J Nucl Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/BF00941852","volume":"22","author":"Kuikka J.T.","year":"1995","unstructured":"Kuikka J.T.; Tiihonen J.; Bergstr\u00f6m K.A.; Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 1995,22(4),346-350","journal-title":"Eur J Nucl Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF01245007","volume":"94","author":"Br\u00fccke T.","year":"1993","unstructured":"Br\u00fccke T.; Kornhuber J.; Angelberger P.; Asenbaum S.; Frassine H.; Podreka I.; SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm (Vienna) 1993,94(2),137-146","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/BF00841395","volume":"24","author":"Bergstr\u00f6m K.A.","year":"1997","unstructured":"Bergstr\u00f6m K.A.; Halldin C.; Hall H.; In vitro and in vivo characterisation of norbeta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 1997,24(6),596-601","journal-title":"Eur J Nucl Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1007\/s002590050346","volume":"25","author":"Booij J.","year":"1998","unstructured":"Booij J.; Knol R.J.J.; Reneman L.; de Bruin K.; Janssen A.G.M.; van Royen E.A.; Iodine-123 labelled nor-\u03b2-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. Eur J Nucl Med Mol Imaging 1998,25(12),1666-1669","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002590050189","volume":"25","author":"Hiltunen J.","year":"1998","unstructured":"Hiltunen J.; Akerman K.K.; Kuikka J.T.; Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur J Nucl Med 1998,25(1),19-23","journal-title":"Eur J Nucl Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pscychresns.2006.08.001","volume":"154","author":"Joensuu M.","year":"2007","unstructured":"Joensuu M.; Tolmunen T.; Saarinen P.I.; Reduced midbrain serotonin transporter availability in drug-na\u00efve patients with depression measured by SERT-specific [123I] nor-\u03b2-CIT SPECT imaging. Psychiatry Res Neuroimaging 2007,154(2),125-131","journal-title":"Psychiatry Res Neuroimaging"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1021\/jm000079i","volume":"43","author":"Wilson A.A.","year":"2000","unstructured":"Wilson A.A.; Ginovart N.; Schmidt M.; Meyer J.H.; Threlkeld P.G.; Houle S.; Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000,43(16),3103-3110","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s002590000365","volume":"27","author":"Houle S.","year":"2000","unstructured":"Houle S.; Ginovart N.; Hussey D.; Meyer J.H.; Wilson A.A.; Imaging the serotonin transporter with positron emission tomography: Initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med Mol Imaging 2000,27(11),1719-1722","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1097\/00004647-200111000-00010","volume":"21","author":"Ginovart N.","year":"2001","unstructured":"Ginovart N.; Wilson A.A.; Meyer J.H.; Hussey D.; Houle S.; Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab 2001,21(11),1342-1353","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/01.WCB.0000040948.67415.05","volume":"22","author":"Huang Y.","year":"2002","unstructured":"Huang Y.; Hwang D.R.; Narendran R.; Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 2002,22(11),1377-1398","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0969-8051(02)00316-5","volume":"29","author":"Wilson A.A.","year":"2002","unstructured":"Wilson A.A.; Ginovart N.; Hussey D.; Meyer J.; Houle S.; In vitro and in vivo characterisation of [11C]-DASB: A probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002,29(5),509-515","journal-title":"Nucl Med Biol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/01.WCB.0000085441.37552.CA","volume":"23","author":"Ichise M.","year":"2003","unstructured":"Ichise M.; Liow J.S.; Lu J.Q.; Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003,23(9),1096-1112","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=62","first-page":"208","volume":"47","author":"Kim J.S.","year":"2006","unstructured":"Kim J.S.; Ichise M.; Sangare J.; Innis R.B.; PET imaging of serotonin transporters with [11C]DASB: Test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med 2006,47(2),208-214","journal-title":"J Nucl Med"},{"key":"ref=63","first-page":"815","volume":"47","author":"Frankle W.G.","year":"2006","unstructured":"Frankle W.G.; Slifstein M.; Gunn R.N.; Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: Reproducibility and comparison of methods. J Nucl Med 2006,47(5),815-826","journal-title":"J Nucl Med"},{"key":"ref=64","first-page":"1129","volume":"37","author":"Abi-Dargham A.","year":"1996","unstructured":"Abi-Dargham A.; Gandelman M.S.; DeErausquin G.A.; SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996,37(7),1129-1133","journal-title":"J Nucl Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00259-007-0621-0","volume":"35","author":"Booij J.","year":"2008","unstructured":"Booij J.; Kemp P.; Dopamine transporter imaging with [123I]FP-CIT SPECT: Potential effects of drugs. Eur J Nucl Med Mol Imaging 2008,35(2),424-438","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00259-005-1767-2","volume":"32","author":"Yanase D.","year":"2005","unstructured":"Yanase D.; Matsunari I.; Yajima K.; Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005,32(7),794-805","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.20748","volume":"21","author":"Lorberboym M.","year":"2006","unstructured":"Lorberboym M.; Treves T.A.; Melamed E.; Lampl Y.; Hellmann M.; Djaldetti R.; [ 123 I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from parkinson\u2019s disease. Mov Disord 2006,21(4),510-514","journal-title":"Mov Disord"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","volume":"15","author":"Benamer H.T.S.","year":"2000","unstructured":"Benamer H.T.S.; Patterson J.; Grosset D.G.; Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2000,15(3),503-510","journal-title":"Mov Disord"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s007020050124","volume":"105","author":"Asenbaum S.","year":"1998","unstructured":"Asenbaum S.; Pirker W.; Angelberger P.; Bencsits G.; Pruckmayer M.; Br\u00fccke T.; [ 123 I]\u03b2-CIT and SPECT in essential tremor and parkinson\u2019s disease. J Neural Transm (Vienna) 1998,105(10-12),1213-1228","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/diagnostics12061402","volume":"12","author":"Cheon M.","year":"2022","unstructured":"Cheon M.; Kim S.M.; Ha S.W.; Kang M.J.; Yang H.E.; Yoo J.; Diagnostic performance for differential diagnosis of atypical parkinsonian syndromes from parkinson\u2019s disease using quantitative indices of (18)FFP-CIT PET\/CT. Diagnostics (Basel) 2022,12(6),1402","journal-title":"Diagnostics (Basel)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00259-014-2882-8","volume":"42","author":"Huertas-Fern\u00e1ndez I.","year":"2015","unstructured":"Huertas-Fern\u00e1ndez I.; Garc\u00eda-G\u00f3mez F.J.; Garc\u00eda-Sol\u00eds D.; Machine learning models for the differential diagnosis of vascular parkinsonism and parkinson\u2019s disease using [123I]FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2015,42(1),112-119","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/jnnp-2012-302618","volume":"84","author":"Ben\u00edtez-Rivero S.","year":"2013","unstructured":"Ben\u00edtez-Rivero S.; Mar\u00edn-Oyaga V.A.; Garc\u00eda-Sol\u00eds D.; Clinical features and 123 I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2013,84(2),122-129","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0404.2011.01583.x","volume":"126","author":"Contrafatto D.","year":"2012","unstructured":"Contrafatto D.; Mostile G.; Nicoletti A.; [123I]FP-CIT-SPECT asymmetry index to differentiate parkinson\u2019s disease from vascular parkinsonism. Acta Neurol Scand 2012,126(1),12-16","journal-title":"Acta Neurol Scand"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/mds.22937","volume":"25","author":"Kalra S.","year":"2010","unstructured":"Kalra S.; Grosset D.G.; Benamer H.T.S.; Differentiating vascular parkinsonism from idiopathic parkinson\u2019s disease: A systematic review. Mov Disord 2010,25(2),149-156","journal-title":"Mov Disord"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/brain\/awh485","volume":"128","author":"Scherfler C.","year":"2005","unstructured":"Scherfler C.; Seppi K.; Donnemiller E.; Voxel-wise analysis of [123I]\u03b2-CIT SPECT differentiates the parkinson variant of multiple system atrophy from idiopathic parkinson\u2019s disease. Brain 2005,128(7),1605-1612","journal-title":"Brain"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1100\/2011\/172893","volume":"11","author":"Politis M.","year":"2011","unstructured":"Politis M.; Loane C.; Serotonergic dysfunction in parkinson\u2019s disease and its relevance to disability. Sci World J 2011,11,1726-1734","journal-title":"Sci World J"},{"key":"ref=77","first-page":"120","volume":"131","author":"Kish S.J.","year":"2008","unstructured":"Kish S.J.; Tong J.; Hornykiewicz O.; Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 2008,131(Pt 1),120-131","journal-title":"Brain"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"Guttman M.","year":"2007","unstructured":"Guttman M.; Boileau I.; Warsh J.; Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease. Eur J Neurol 2007,14(5),523-528","journal-title":"Eur J Neurol"},{"key":"ref=79","first-page":"39","volume":"91","author":"Kish S.J.","year":"2003","unstructured":"Kish S.J.; Biochemistry of Parkinson\u2019s disease: Is a brain serotonergic deficiency a characteristic of idiopathic Parkinson\u2019s disease? Adv Neurol 2003,91,39-49","journal-title":"Adv Neurol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41583-021-00542-9","volume":"23","author":"Blesa J.","year":"2022","unstructured":"Blesa J.; Foffani G.; Dehay B.; Bezard E.; Obeso J.A.; Motor and non-motor circuit disturbances in early Parkinson disease: Which happens first? Nat Rev Neurosci 2022,23(2),115-128","journal-title":"Nat Rev Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e28643","DOI":"10.1097\/MD.0000000000028643","volume":"101","author":"Kang K.W.","year":"2022","unstructured":"Kang K.W.; Choi S.M.; Kim B.C.; Gender differences in motor and non-motor symptoms in early Parkinson disease. Medicine (Baltimore) 2022,101(3),e28643","journal-title":"Medicine (Baltimore)"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/NRE-210146","volume":"49","author":"Liguori S.","year":"2021","unstructured":"Liguori S.; Moretti A.; Palomba A.; Non-motor impairments affect walking kinematics in Parkinson disease patients: A cross-sectional study. NeuroRehabilitation 2021,49(3),481-489","journal-title":"NeuroRehabilitation"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10286-021-00771-z","volume":"31","author":"Chaudhuri K.R.","year":"2021","unstructured":"Chaudhuri K.R.; Thirty years of research on autonomic dysfunction, non-motor features, and endophenotypes in Parkinson disease. Clin Auton Res 2021,31(1),37-39","journal-title":"Clin Auton Res"},{"key":"ref=84","first-page":"508","volume":"68","author":"Sahli H.","year":"2018","unstructured":"Sahli H.; Seddik L.; R\u00e9my P.; Non-motor symptoms of parkinson disease and their management. Rev Prat 2018,68(5),508-512","journal-title":"Rev Prat"},{"key":"ref=85","first-page":"227","volume":"46","author":"Weintraub D.","year":"2005","unstructured":"Weintraub D.; Newberg A.B.; Cary M.S.; Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in parkinson\u2019s disease. J Nucl Med 2005,46(2),227-232","journal-title":"J Nucl Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/WNL.36.8.1130","volume":"36","author":"Santamar\u00eda J.","year":"1986","unstructured":"Santamar\u00eda J.; Tolosa E.; Valles A.; Parkinson\u2019s disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986,36(8),1130-1133","journal-title":"Neurology"},{"key":"ref=87","author":"Joling M.","year":"2017","unstructured":"Joling M.; van den Heuvel O.A.; Berendse H.W.; Booij J.; Vriend C.; Serotonin transporter binding and anxiety symptoms in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1176\/appi.ajp.163.1.8","volume":"163","author":"Sibille E.","year":"2006","unstructured":"Sibille E.; Lewis D.A.; SERT-ainly involved in depression, but when? Am J Psychiatry 2006,163(1),8-11","journal-title":"Am J Psychiatry"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jad.2015.07.034","volume":"186","author":"Kambeitz J.P.","year":"2015","unstructured":"Kambeitz J.P.; Howes O.D.; The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord 2015,186,358-366","journal-title":"J Affect Disord"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00259-008-1057-x","volume":"36","author":"Ruh\u00e9 H.G.","year":"2009","unstructured":"Ruh\u00e9 H.G.; Booij J.; Reitsma J.B.; Schene A.H.; Serotonin transporter binding with [123I]\u03b2-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 2009,36(5),841-849","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/syn.20954","volume":"65","author":"Macgillivray L.","year":"2011","unstructured":"Macgillivray L.; Reynolds K.B.; Sickand M.; Rosebush P.I.; Mazurek M.F.; Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra. Synapse 2011,65(11),1166-1172","journal-title":"Synapse"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"VD01","DOI":"10.7860\/JCDR\/2015\/11394.5583","volume":"9","author":"Dixit S.","year":"2015","unstructured":"Dixit S.; Khan S.A.; Azad S.; A case of SSRI induced irreversible parkinsonism. J Clin Diagn Res 2015,9(2),VD01-VD02","journal-title":"J Clin Diagn Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/WNF.0b013e318210ea3e","volume":"34","author":"Mileti\u0107 V.","year":"2011","unstructured":"Mileti\u0107 V.; Relja M.; Citalopram-induced parkinsonian syndrome: Case report. Clin Neuropharmacol 2011,34(2),92-93","journal-title":"Clin Neuropharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2710.2001.00307.x","volume":"26","author":"Pina Latorre M.A.","year":"2001","unstructured":"Pina Latorre M.A.; Modrego P.J.; Rodilla F.; Catal\u00e1n C.; Calvo M.; Parkinsonism and parkinson\u2019s disease associated with long-term administration of sertraline. J Clin Pharm Ther 2001,26(2),111-112","journal-title":"J Clin Pharm Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4088\/JCP.v60n0611d","volume":"60","author":"G\u00f6n\u00fcl A.S.","year":"1999","unstructured":"G\u00f6n\u00fcl A.S.; Aksu M.; SSRI-induced parkinsonism may be an early sign of future parkinson\u2019s disease. J Clin Psychiatry 1999,60(6),410","journal-title":"J Clin Psychiatry"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s007020050053","volume":"105","author":"Di Rocco A.","year":"1998","unstructured":"Di Rocco A.; Brannan T.; Prikhojan A.; Yahr M.D.; Sertraline induced parkinsonim. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm (Vienna) 1998,105(2-3),247-251","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1109\/TIP.2022.3193288","volume":"31","author":"Tang W.","year":"2022","unstructured":"Tang W.; He F.; Liu Y.; Duan Y.; MATR: Multimodal medical image fusion via multiscale adaptive transformer. IEEE Trans Image Process 2022,31,5134-5149","journal-title":"IEEE Trans Image Process"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3192661","DOI":"10.1109\/TMM.2022.3192661","volume":"2022","author":"Tang W.","year":"2022","unstructured":"Tang W.; He F.; Liu Y.; YDTR: Infrared and visible image fusion via y-shape dynamic transformer. IEEE Trans Image Process 2022,2022,3192661","journal-title":"IEEE Trans Image Process"}],"container-title":["Current Medical Imaging Formerly Current Medical Imaging Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573405619666230124142725","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213091\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573405619666230124142725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T09:58:45Z","timestamp":1689933525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213091\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573405619666230124142725","relation":{},"ISSN":["1573-4056"],"issn-type":[{"type":"print","value":"1573-4056"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e240123213091"}}